Synkopen – Differenzialdiagnosen und Behandlungsmöglichkeiten

Die zugrundeliegenden Ursachen für eine Synkope sind vielfältig und mit deutlich differierender Prognose behaftet. Ein strukturiertes Vorgehen ist essenziell, um Differenzialdiagnosen wie einen epileptischen Anfall zu erkennen, Hochrisikopatienten zu identifizieren und eine adäquate Therapie zu gewährleisten. Dieser Artikel gibt einen Überblick über aktuelle Empfehlungen zur Diagnostik und Therapie der Synkope.

Abstract

Syncope is a sudden loss of consciousness (transient loss of consciousness, TLOC) caused by a lack of cerebral perfusion that resolves spontaneously and completely after a short period of time [1]. With a lifetime prevalence of 40% and constituting about 1% of all emergency department admissions, syncope is a common and medically relevant problem [2] [3]. The underlying causes of syncope are diverse and associated with significantly different prognoses. A structured approach is essential to identify high-risk patients and ensure appropriate treatment. This article aims at providing an overview of the current recommendations for the diagnosis and treatment of syncope.

Schlüsselwörter

Synkope - orthostatisch - kardial - transienter Bewusstseinsverlust - Herzschrittmachertherapie

Keywords

syncope - orthostatic - cardiac - transient loss of consciousness - cardiac pacing

• Literatur

• 1 Brignole M, Moya A, De Lange FJ. et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 2018; 39 (21) 1883-1948
• 2 Sandhu RK, Sheldon RS. Syncope in the Emergency Department. Front Cardiovasc Med 2019; 6: 1-5
• 3 Ghariq M, van den Hout WB, Dekkers OM. et al. Diagnostic and societal impact of implementing the Syncope Guidelines of the European Society of Cardiology (SYNERGY study). BMC Med 2023;
• 4 Elpidoforos S, Soteriades MD, Jane C. et al. Incidence and prognosis of Syncope. N Engl J Med 2002; 347 (12) 878-885
• 5 Jardine DL. Vasovagal syncope: New physiologic insights. Cardiol Clin 2013; 31 (01) 75-87
• 6 Saklani P, Krahn A, Klein G. Syncope. Circulation 2013; 127 (12) 1330-1339
• 7 Wieling W, Kaufmann H, Claydon VE. et al. Diagnosis and treatment of orthostatic hypotension. Lancet Neurol 2022; 21 (08) 735-746
• 8 da Silva RMFL, Brugada J. Cardiac and Vascular Causes of Syncope and Atherosclerosis. Curr Cardiol Rep 2022; 24 (10) 1241-1249
• 9 Hadjikoutis S, O’Callaghan P, Smith PEM. The investigation of syncope. Seizure 2004; 13 (08) 537-548
• 10 Hoefnagels WAJ, Padberg GW, Overweg J. et al. Transient loss of consciousness: The value of the history for distinguishing seizure from syncope. J Neurol 1991; 238 (01) 39-43
• 11 Raj V, Rowe AA, Fleisch SB. et al. Psychogenic pseudosyncope: Diagnosis and management. Auton Neurosci Basic Clin 2014; 184: 66-72
• 12 Tannemaat MR, Van Niekerk J, Reijntjes RH. et al. The semiology of tilt-induced psychogenic pseudosyncope. Neurology 2013; 81 (08) 752-758
• 13 Brignole M, Moya A, De Lange FJ. et al. Practical Instructions for the 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 2018; 39 (21) e43-80
• 14 Veltmann C, Bosch R, Boer J. et al. Recommendation for the indication of implantable loop recorders: Position paper of the working group electrophysiology and rhythmology of the German Cardiac Society. Kardiologie 2023; 17 (06) 389-405
• 15 Sheldon R, Connolly S, Rose S. et al. Prevention of Syncope Trial (POST): A randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Circulation 2006; 113 (09) 1164-1167
• 16 Butter C, Eckardt L, Israel CW. et al. Schrittmacher- und kardiale Resynchronisationstherapie. Kommentar zu den Leitlinien (2021) der ESC. Kardiologie 2022; 16: 383-390
• 17 Jankovic J, Gilden JL, Hiner BC. et al. Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine. Am J Med 1993; 95 (01) 38-48
• 18 Phillip A, Low MD, Janice L. et al. Efficacy of Midodrine vs Placebo in Neurogenic Orthostatic Hypotension. JAMA 1997; 277 (13) 1046-1051
• 19 Vahanian A, Beyersdorf F, Praz F. et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Rev Esp Cardiol 2022; 75 (06) 524
• 20 Glikson M, Nielsen JC, Kronborg MB. et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021; 42 (35) 3427-3520
• 21 Zeppenfeld K, Tfelt-Hansen J, de Riva M. et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022; 43 (40) 3997-4126